Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of Quetiapine Extended-Release (Seroquel XR) and Risperidone in the treatment of depressive symptoms, in schizophrenic or schizoaffective patients: A randomized, open label, flexible-dose, parallel group, non inferiority, 12-week study

Next Previous
Search
Trial Profile

Comparison of Quetiapine Extended-Release (Seroquel XR) and Risperidone in the treatment of depressive symptoms, in schizophrenic or schizoaffective patients: A randomized, open label, flexible-dose, parallel group, non inferiority, 12-week study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quetiapine (Primary) ; Risperidone
  • Indications Depression; Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Acronyms ExAttitude
  • Sponsors AstraZeneca

Most Recent Events

  • 01 May 2014 Results published in the International Clinical Psychopharmacology.
  • 18 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 18 Feb 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top